Health & Biotech
Imricor is the global leader in the development and manufacture of MRI compatible devices for performing cardiac ablations. A cardiac ablation is a procedure conducted by an electrophysiologist where a catheter is guided into the heart with the purpose of burning/ablating the tissue responsible for causing the arrythmia (irregular heartbeat).
The cardiac ablation market, which is over US$8bn per year, currently uses X-Ray guidance to identify the location in the heart that requires treatment. X-Ray as an imaging tool has limitations as it does not show the soft tissue of the heart and exposes the patients and physicians to repeated radiation.
Imricor has the only cardiac ablation devices in the world that have been proven to be safe and effective inside the magnetic field generated by an MRI and, after 18 years of research and development, is now commercialising globally with approvals in Europe, the Middle East and soon to be in both Australia (2024) and the US (2025). The technology is protected by over 70 global patents.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
First US patient treated in Imricor cardiac ablation trial
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ASX Quarterly Health Wrap – Who kicked off a pivotal trial last quarter?
Health & Biotech
Imricor Medical Systems raising $35m to fund growth strategy
News
Closing Bell: Rotating to new highs, global markets are busy popping small caps back into their assets
Health & Biotech
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Health & Biotech
ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo
Health & Biotech
ASX Health Stocks: Cleo gains FDA momentum for its ovarian cancer detection tech
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as M&A activity heats up
Health & Biotech
Imricor starts global trial for US FDA approval
Stockhead TV
Break it Down: Imricor has its finger on the pulse
News
Skin in the game: Which ASX directors are upping stakes in their companies?
Health & Biotech
Top ASX biotechs catching the eye of analysts and fund managers in 2024 – Part 2
Health & Biotech
With FDA approval close, Echo IQ’s AI platform is set to disrupt US heart disease market
Health & Biotech
ScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reports
Health & Biotech